We use cookies for a better user experience. Read our Privacy Policy

I Agree

Adrenocorticotropic Hormone [ACTH] Market Trends, 2021-2031

Adrenocorticotropic Hormone [ACTH] Market (Source: Natural and Synthetic; Indication: Rheumatology, Neurology, Nephrotic Syndrome, Ophthalmology, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Understanding Care Patterns of High Risk Patients Gains Importance During COVID-19 Pandemic

The entire U.S. healthcare system is planning, preparing, and collaborating to manage the COVID-19 pandemic. In order to maintain continuous supply chains, manufacturers in the adrenocorticotropic hormone (ACTH) market are striving to understand care patterns of high-risk patients and those with respiratory diseases. Manufacturers are establishing robust supply chains with urgent care centers, retail clinics in pharmacies, and workplace clinics to keep economies running during the pandemic. Since emergency departments are already stretched thin, these sites can act like wetlands to help absorb part of the overflow of patients with or without illnesses.

Telehealth services is emerging as a new business model for stakeholders in the adrenocorticotropic hormone (ACTH) market. These services are found to be most effective first line of access for non-elderly Americans with mild illness or with a risk of COVID-19.

adrenocorticotropic hormone (acth) market infographic

To know the scope of our report Get a Sample on Adrenocorticotropic Hormone [ACTH] Market

Side Effects of ACTH Require Management by Healthcare Providers

The adrenocorticotropic hormone (ACTH) market is expected to surpass US$ 1.91 Bn by 2031. However, possible side effects of ACTH such as bone loss, indigestion, and muscle weakness are causing concerns among patients, pertaining to corticotropin as parenteral solution for injection. Hence, manufacturers are working closely with healthcare providers to create awareness about the management of side effects.

ACTH is being made available online for screening of patients presumed to have adrenocortical insufficiency. The growing incidence of stress and anxiety among individuals is acting as a key driver of the market, since stress may increase ACTH secretion in the body. On the other hand, ACTH is being used therapeutically as a drug to treat multiple sclerosis and infantile spasms.

Get a glimpse of the in-depth analysis through our Report Brochure

High Prevalence of Cushing’s Disease, Hypopituitarism Creating Revenue Opportunities

ACTH blood tests are used in conjunction with cortisol tests to help detect, diagnose, and monitor conditions associated with excessive or deficient cortisol. The high prevalence of Cushing’s disease, Cushing syndrome, Addison disease, and hypopituitarism are contributing to the growth of the adrenocorticotropic hormone (ACTH) market, which is slated to clock a CAGR of 3.9% during the forecast period.

Measuring both cortisol and ACTH can help to differentiate different health conditions since the level of ACTH normally changes in the opposite direction to the level of cortisol. Since too much cortisol can lead to health issues such as acne, obesity, red face, and the likes, such findings are generating revenue opportunities for stakeholders in the adrenocorticotropic hormone (ACTH) market.

Abnormal Test Results, Ectopic Production of ACTH Influencing Market Growth

Individuals with insufficient cortisol production may exhibit symptoms including fatigue, diarrhea, and increased skin pigmentation. Such health issues are increasing revenue flow in the adrenocorticotropic hormone (ACTH) market. While ACTH is used to diagnose adrenal insufficiency, the ACTH stimulation test is being preferred for diagnosis. However, taking certain medications including oral, steroid or topical may cause abnormal results. Awareness is being created about the shortcomings of ACTH stimulation tests and management techniques are being implemented to avoid abnormal test results.

In addition to excess of ACTH from the pituitary gland, it can also generate from elsewhere in the body. This medical condition is known as ectopic production of ACTH, which is generated from tumors in different parts of the body.

adrenocorticotropic hormone (acth) market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Trust-based relationships are gaining prominence during the COVID-19 pandemic, which involve reliable community organizations educating patients about precautions to be taken during the ongoing pandemic situation. Conditions such as ectopic ACTH syndrome (EAS) and non-neoplastic hypercortisolemia (NNH) tend to exhibit glucocorticoid resistance. Such findings are creating value-grab opportunities for companies in the adrenocorticotropic hormone (ACTH) market. It has been found that corticotropin as a parenteral solution for injection can lead to possible side effects including back pain, menstrual irregularities, and hyperpigmentation. Hence, stakeholders in the adrenocorticotropic hormone (ACTH) market should work closely with clinicians and healthcare providers to increase awareness about effective management of side effects to improve patient outcomes.

Adrenocorticotropic Hormone (ACTH) Market: Overview

  • According to Transparency Market Research’s latest market report on the global adrenocorticotropic hormone (ACTH) market for the historical period of 2017–2019 and forecast period of 2021–2031, multiple clinical applications and rise in prevalence of various chronic diseases are projected to drive the global adrenocorticotropic hormone (ACTH) market
  • According to the report, the global adrenocorticotropic hormone (ACTH) market was valued at US$ 1.3 Bn in 2020 and is anticipated to expand at a CAGR of 3.9% from 2021 to 2031

Multiple Applications, Rise in Prevalence of Various Chronic Diseases to Drive Global Market

  • Corticotropin is used to treat conditions such as nephrotic syndrome (NS), rheumatology-related conditions, multiple sclerosis (MS), ankylosing spondylitis (AS), and infantile spasms (IS)
  • H.P. Acthar Gel was Questcor Pharmaceuticals, Inc.'s primary corticotropin product, which was acquired by Mallinckrodt in August 2014. The U.S. FDA approved Acthar for the treatment of 19 indications.
  • The rate of infantile spasm is estimated to be 2.5 to 6.0 per 10,000 live births. Its prevalence rate is 1.5 to 2.0 per 10,000 children aged 10 years or younger, based on data published in the National Organization for Rare Disorders, Inc. Rise in cases of target diseases and application of corticotropin in various indications drive the global adrenocorticotropic hormone (ACTH) market.

Increase in Investment in Research & Development

  • Demand for development of newer and technologically enhanced products is rising globally, owing to the treatment efficiency of drugs. Hence, major players operating in the market invest in research & development programs in order to develop new drugs.
  • Current oral glucocorticoid replacement therapy for patients with adrenal insufficiency (AI) does not truly mimic the normal physiologic cortisol rhythm, a nadir at bedtime, and gradually rising levels to the early morning peak between 3 am and 6 am before waking
  • Continuous subcutaneous hydrocortisone infusion therapy administered via an insulin pump to deliver hydrocortisone is another novel method of treatment of ACTH deficiency
  • Pexacerfont, a corticotropin-releasing hormone-1 (CRH1) receptor antagonist, is currently under investigation for the treatment of generalized anxiety disorder. Recent research has linked the activation of CRH1 receptor with euphoric feelings that accompany alcohol consumption. A CRH1 receptor antagonist developed by Pfizer, CP-154,526, is under investigation for the potential treatment of alcoholism.
  • Rise in investment in research & development by key players is likely to boost the growth of the global market during the forecast period

High Cost of Treatment in U.S. to Restrain Adrenocorticotropic Hormone (ACTH) Market

  • ACTH is priced higher than other agents, at around US$ 30,000 per vial. H.P. Acthar Gel, which cost around US$ 50 in 2000, was selling for US$ 28,000 for a 5 ml vial in 2012.
  • In February 2015, Questcor Pharmaceuticals, which acquired the rights to market Synacthen Depot, raised its price from US$ 35.66 to US$ 801.19 per vial. The cost of the required six-week treatment skyrocketed from about US$ 750 to nearly US$ 17,000. Questcor reportedly increased the price of its best-selling drug Acthar Gel by 85,000%, from US$ 50 in 2000 to US$ 34,000 per vial in 2017.
  • Adrenocorticotrophic hormone (ACTH) and prednisone are both used to treat infantile spasms (IS). However, the cost of ACTH injection is more than 100 times the cost of oral prednisolone.
  • These diseases are life-threatening and do not have a permanent cure; hence, the cost of lifelong treatment renders it unaffordable, leading to decline in the number of patients preferring to avail the treatment

Adrenocorticotropic Hormone (ACTH) Market: Competition Landscape

  • This report profiles major players in the global adrenocorticotropic hormone (ACTH) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The adrenocorticotropic hormone (ACTH) market is highly consolidated, with the presence of a few large players in international markets and few small players in regional markets. The top four to five players hold majority share of the global adrenocorticotropic hormone (ACTH) market.
  • Prominent players operating in the global adrenocorticotropic hormone (ACTH) market include
    • Mallinckrodt plc
    • Pfizer, Inc.
    • Novartis AG
    • Merck KGaA
    • Ferring B.V.
    • Avantor, Inc.
    • Viatris, Inc.
    • Hikma Pharmaceuticals plc
  • The report on the global adrenocorticotropic hormone (ACTH) market discusses individual strategies, followed by company profiles of adrenocorticotropic hormone (ACTH) providers. The competition landscape section has been included in the global adrenocorticotropic hormone (ACTH) market report to provide readers with a dashboard view of key market players operating in the global adrenocorticotropic hormone (ACTH) market.

Adrenocorticotropic Hormone (ACTH) Market: Key Developments

  • In July 2021, Mallinckrodt announced inclusion of Acthar Gel (repository corticotropin injection) in New European Respiratory Society (ERS) Treatment Guidelines for patients with pulmonary sarcoidosis
  • In June 2021, Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies, and applied materials industries, announced it has completed its previously announced acquisition of Ritter GmbH and its affiliates
  • In March 2021, Mallinckrodt announced the U.S. Food and Drug Administration (FDA) approval for the updated Acthar Gel (repository corticotropin injection) label
  • In August 2020, Upsher-Smith Laboratories, LLC (Upsher-Smith) and AmbioPharm, Inc. (AmbioPharm) announced that the companies entered into a partnership agreement to develop and market Corticotropin Injection in the U.S.
  • In China, a research study on the role of corticotropin releasing factor in the neuroimmune mechanisms of depression is underway. This study was supported by the National Natural Science Foundation of China, the FHS Internal Collaboration Proposals 2017, the University of Macau, and the Science and Technology Development Fund (FDCT) of Macao.

Adrenocorticotropic Hormone (ACTH) Market Snapshot

Attribute

Detail

Market Size Value in 2020 (Base Year)

US$ 1.3 Bn

Market Forecast Value in 2031

US$ 1.91 Bn

Growth Rate (CAGR)

3.9%

Forecast Period

2021-2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, parent industry overview, etc.

Competition Landscape

  • Market Share Analysis, by Company, 2020
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, key financials, etc.

Format

Electronic (PDF)

Market Segmentation

  • Source
    • Natural
    • Synthetic
  • Indication
    • Rheumatology
    • Neurology
    • Nephrotic Syndrome
    • Ophthalmology
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Sales

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Ambio Pharm, Inc.
  • Armor Pharma
  • Avantor, Inc.
  • BCN Peptides S.A.
  • BIOVECTRA
  • Ferring B.V.
  • Hikma Pharmaceuticals plc
  • Mallinckrodt Pharmaceuticals
  • Merck KGaA
  • Novartis AG
  • Novus Biologicals
  • Pfizer, Inc.
  • Piramal Pharma Solutions
  • PolyPeptide Group
  • SAJJALA BIO LABS
  • Sichuan Xieli Pharmaceutical Co., Ltd.
  • Viatris, Inc.

Customization Scope

Available upon Request

Pricing

Available upon Request

Adrenocorticotropic Hormone (ACTH) Market – Segmentation

Source
  • Natural
  • Synthetic
Indication
  • Rheumatology
  • Neurology
  • Nephrotic Syndrome
  • Ophthalmology
  • Others
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of adrenocorticotropic hormone [ACTH] market?

Adrenocorticotropic hormone (ACTH) market is expected to surpass US$ 1.91 Bn by 2031

What is the anticipated CAGR of the adrenocorticotropic hormone [ACTH] market in the forecast period?

Adrenocorticotropic hormone (ACTH) market is projected to expand at a CAGR of 3.9% from 2021 to 2031

What are the key driving factors for the growth of the adrenocorticotropic hormone [ACTH] market?

Adrenocorticotropic hormone (ACTH) market is driven by rise in prevalence of various chronic diseases and rise in investments in research & development by key players

Which region is expected to project the highest market share in the global adrenocorticotropic hormone [ACTH] market?

North America dominated the global adrenocorticotropic hormone (ACTH) market in 2020 and the trend is likely to continue during the forecast period

Who are the key players in the global adrenocorticotropic hormone [ACTH] market?

Key players operating in the global adrenocorticotropic hormone (ACTH) market include Mallinckrodt plc, Pfizer, Inc., Novartis AG, Merck KGaA, Ferring B.V., Avantor, Inc., Viatris, Inc., Hikma Pharmaceuticals plc

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Adrenocorticotropic Hormone (ACTH) Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Top 3 Players Operating in the Market Space

    5.2. Regulatory Scenario

    5.3. Export-Import Scenario

    5.4. Comparison Study of Synthetic & Natural Adrenocorticotropic Hormone

    5.5. Pipeline Analysis

    5.6. COVID-19 Pandemic Impact on Industry

6. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Source

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Source, 2017–2031

        6.3.1. Natural

        6.3.2. Synthetic

    6.4. Market Attractiveness Analysis, by Source

7. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Indication

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Indication, 2017–2031

        7.3.1. Rheumatology

        7.3.2. Neurology

        7.3.3. Nephrotic Syndrome

        7.3.4. Ophthalmology

        7.3.5. Others

    7.4. Market Attractiveness Analysis, by Indication

8. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Country/Region

10. North America Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Source, 2017–2031

        10.2.1. Natural

        10.2.2. Synthetic

    10.3. Market Value Forecast, by Indication, 2017–2031

        10.3.1. Rheumatology

        10.3.2. Neurology

        10.3.3. Nephrotic Syndrome

        10.3.4. Ophthalmology

        10.3.5. Others

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Source

        10.6.2. By Indication

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Source, 2017–2031

        11.2.1. Natural

        11.2.2. Synthetic

    11.3. Market Value Forecast, by Indication, 2017–2031

        11.3.1. Rheumatology

        11.3.2. Neurology

        11.3.3. Nephrotic Syndrome

        11.3.4. Ophthalmology

        11.3.5. Others

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Country/Sub-Region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Source

        11.6.2. By Indication

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-Region

12. Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Source, 2017–2031

        12.2.1. Natural

        12.2.2. Synthetic

    12.3. Market Value Forecast, by Indication, 2017–2031

        12.3.1. Rheumatology

        12.3.2. Neurology

        12.3.3. Nephrotic Syndrome

        12.3.4. Ophthalmology

        12.3.5. Others

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-Region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Source

        12.6.2. By Indication

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-Region

13. Latin America Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Source, 2017–2031

        13.2.1. Natural

        13.2.2. Synthetic

    13.3. Market Value Forecast, by Indication, 2017–2031

        13.3.1. Rheumatology

        13.3.2. Neurology

        13.3.3. Nephrotic Syndrome

        13.3.4. Ophthalmology

        13.3.5. Others

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-Region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Source

        13.6.2. By Indication

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-Region

14. Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Source, 2017–2031

        14.2.1. Natural

        14.2.2. Synthetic

    14.3. Market Value Forecast, by Indication, 2017–2031

        14.3.1. Rheumatology

        14.3.2. Neurology

        14.3.3. Nephrotic Syndrome

        14.3.4. Ophthalmology

        14.3.5. Others

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Country/Sub-Region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Source

        14.6.2. By Indication

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-Region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2020

    15.3. Company Profiles

        15.3.1. Ambio Pharm, Inc.

            15.3.1.1. Company Description

            15.3.1.2. Business Overview

            15.3.1.3. Financial Overview

            15.3.1.4. Strategic Overview

            15.3.1.5. SWOT Analysis

        15.3.2. Armor Pharma

            15.3.2.1. Company Description

            15.3.2.2. Business Overview

            15.3.2.3. Financial Overview

            15.3.2.4. Strategic Overview

            15.3.2.5. SWOT Analysis

        15.3.3. Avantor, Inc.

            15.3.3.1. Company Description

            15.3.3.2. Business Overview

            15.3.3.3. Financial Overview

            15.3.3.4. Strategic Overview

            15.3.3.5. SWOT Analysis

        15.3.4. BCN Peptides S.A.

            15.3.4.1. Company Description

            15.3.4.2. Business Overview

            15.3.4.3. Financial Overview

            15.3.4.4. Strategic Overview

            15.3.4.5. SWOT Analysis

        15.3.5. BIOVECTRA

            15.3.5.1. Company Description

            15.3.5.2. Business Overview

            15.3.5.3. Financial Overview

            15.3.5.4. Strategic Overview

            15.3.5.5. SWOT Analysis

        15.3.6. Ferring B.V.

            15.3.6.1. Company Description

            15.3.6.2. Business Overview

            15.3.6.3. Financial Overview

            15.3.6.4. Strategic Overview

            15.3.6.5. SWOT Analysis

        15.3.7. Hikma Pharmaceuticals plc

            15.3.7.1. Company Description

            15.3.7.2. Business Overview

            15.3.7.3. Financial Overview

            15.3.7.4. Strategic Overview

            15.3.7.5. SWOT Analysis

        15.3.8. Mallinckrodt Pharmaceuticals

            15.3.8.1. Company Description

            15.3.8.2. Business Overview

            15.3.8.3. Financial Overview

            15.3.8.4. Strategic Overview

            15.3.8.5. SWOT Analysis

        15.3.9. Merck KGaA

            15.3.9.1. Company Description

            15.3.9.2. Business Overview

            15.3.9.3. Financial Overview

            15.3.9.4. Strategic Overview

            15.3.9.5. SWOT Analysis

        15.3.10. Novartis AG

            15.3.10.1. Company Description

            15.3.10.2. Business Overview

            15.3.10.3. Financial Overview

            15.3.10.4. Strategic Overview

            15.3.10.5. SWOT Analysis

        15.3.11. Novus Biologicals

            15.3.11.1. Company Description

            15.3.11.2. Business Overview

            15.3.11.3. Financial Overview

            15.3.11.4. Strategic Overview

            15.3.11.5. SWOT Analysis

        15.3.12. Pfizer, Inc.

            15.3.12.1. Company Description

            15.3.12.2. Business Overview

            15.3.12.3. Financial Overview

            15.3.12.4. Strategic Overview

            15.3.12.5. SWOT Analysis

        15.3.13. Piramal Pharma Solutions

            15.3.13.1. Company Description

            15.3.13.2. Business Overview

            15.3.13.3. Financial Overview

            15.3.13.4. Strategic Overview

            15.3.13.5. SWOT Analysis

        15.3.14. PolyPeptide Group

            15.3.14.1. Company Description

            15.3.14.2. Business Overview

            15.3.14.3. Financial Overview

            15.3.14.4. Strategic Overview

            15.3.14.5. SWOT Analysis

        15.3.15. SAJJALA BIO LABS

            15.3.15.1. Company Description

            15.3.15.2. Business Overview

            15.3.15.3. Financial Overview

            15.3.15.4. Strategic Overview

            15.3.15.5. SWOT Analysis

        15.3.16. Sichuan Xieli Pharmaceutical Co., Ltd.

            15.3.16.1. Company Description

            15.3.16.2. Business Overview

            15.3.16.3. Financial Overview

            15.3.16.4. Strategic Overview

            15.3.16.5. SWOT Analysis

        15.3.17. Viatris Inc.

            15.3.17.1. Company Description

            15.3.17.2. Business Overview

            15.3.17.3. Financial Overview

            15.3.17.4. Strategic Overview

            15.3.17.5. SWOT Analysis

List of Tables

Table 01: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 02: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

Table 03: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 07: North America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 08: North America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 11: Europe Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Europe Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 15: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 16: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 19: Latin America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 20: Latin America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 23: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 24: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 

List of Figure

Figure 01: Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Adrenocorticotropic Hormone (ACTH) Market Value Share, by Source, 2020

Figure 03: Adrenocorticotropic Hormone (ACTH) Market Value Share, by Indication, 2020

Figure 04: Adrenocorticotropic Hormone (ACTH) Market Value Share, by Distribution Channel, 2020

Figure 05: Global Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031

Figure 06: Global Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031

Figure 07: Global Adrenocorticotropic Hormone (ACTH) Market Revenue (US$ Mn), by Natural, 2017–2031

Figure 08: Global Adrenocorticotropic Hormone (ACTH) Market Revenue (US$ Mn), by Synthetic, 2017–2031

Figure 09: Global Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Indication, 2020 and 2031

Figure 10: Global Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031

Figure 11: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn), by Rheumatology, 2017‒2031

Figure 12: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn), by Neurology, 2017‒2031

Figure 13: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn), by Nephrotic Syndrome, 2017‒2031

Figure 14: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn), by Ophthalmology, 2017‒2031

Figure 15: Global Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn), by Others, 2017–2031

Figure 16: Global Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 17: Global Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 18: Global Adrenocorticotropic Hormone (ACTH) Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031

Figure 19: Global Adrenocorticotropic Hormone (ACTH) Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

Figure 20: Global Adrenocorticotropic Hormone (ACTH) Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031

Figure 21: Global Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Region, 2020 and 2031

Figure 22: Global Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Region, 2021–2031

Figure 23: North America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 24: North America Adrenocorticotropic Hormone (ACTH) Market Value Share, by Country, 2020 & 2031

Figure 25: North America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Country, 2021–2031

Figure 26: North America Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031

Figure 27: North America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031

Figure 28: North America Adrenocorticotropic Hormone (ACTH) Market Value Share (%), by Indication, 2020 and 2031

Figure 29: North America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031

Figure 30: North America Adrenocorticotropic Hormone (ACTH) Market Value Share (%), by Distribution Channel, 2020 and 2031

Figure 31: North America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 32: Europe Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, 2017–2031

Figure 33: Europe Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 34: Europe Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 35: Europe Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031

Figure 36: Europe Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031

Figure 37: Europe Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Indication, 2020 and 2031

Figure 38: Europe Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031

Figure 39: Europe Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 40: Europe Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 41: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, 2017–2031

Figure 42: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 43: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 44: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031

Figure 45: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031

Figure 46: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Indication, 2020 and 2031

Figure 47: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031

Figure 48: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 49: Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 50: Latin America Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, 2017–2031

Figure 51: Latin America Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 52: Latin America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 53: Latin America Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031

Figure 54: Latin America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031

Figure 55: Latin America Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Indication, 2020 and 2031

Figure 56: Latin America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031

Figure 57: Latin America Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 58: Latin America Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 59: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value (US$ Mn) Forecast, 2017–2031

Figure 60: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 61: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 62: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Source, 2020 and 2031

Figure 63: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Source, 2021–2031

Figure 64: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Indication, 2020 and 2031

Figure 65: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Indication, 2021–2031

Figure 66: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 67: Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved